Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent
Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.
대표청구항▼
1. A device comprising a. a stent; andb. a coating on the stent comprising five layers: a first layer comprising at least one bioabsorbable polymer; a second layer comprising at least one active agent; a third layer comprising at least one bioabsorbable polymer; a fourth layer comprising at least on
1. A device comprising a. a stent; andb. a coating on the stent comprising five layers: a first layer comprising at least one bioabsorbable polymer; a second layer comprising at least one active agent; a third layer comprising at least one bioabsorbable polymer; a fourth layer comprising at least one active agent; and an outer layer comprising at least one bioabsorbable polymer; wherein each of said bioabsorbable polymer layers comprises a separately sintered bioabsorbable polymer layer;wherein said outer layer comprising said at least one bioabsorbable polymer is sufficiently thin so that the active agent is present in crystalline form on at least one region of an outer surface of the coating opposite the stent and wherein 50% or less of the total amount of active agent in the coating is released after 24 hours in vitro elution;wherein the active agent comprises a macrolide immunosuppressive (limus) drug. 2. The device of claim 1, wherein in vitro elution is carried out in a 1:1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37° C.; wherein the amount of active agent released is determined by measuring UV absorption. 3. The device of claim 2 wherein UV absorption is detected at 278 nm by a diode array spectrometer. 4. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by cluster secondary ion mass spectrometry (cluster SIMS). 5. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by generating cluster secondary ion mass spectrometry (cluster SIMS) depth profiles. 6. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by time of flight secondary ion mass spectrometry (TOF-SIMS). 7. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by atomic force microscopy (AFM). 8. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by X-ray spectroscopy. 9. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by electronic microscopy. 10. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by Raman spectroscopy. 11. The device of claim 1, wherein between 25% and 45% of the total amount of active agent in the coating is released after 24 hours in vitro elution in a 1:1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37° C.; wherein the amount of the active agent released is determined by measuring UV absorption at 278 nm by a diode array spectrometer. 12. The device of claim 1, wherein the active agent is at least 50% crystalline. 13. The device of claim 1, wherein the active agent is at least 75% crystalline. 14. The device of claim 1, wherein the active agent is at least 90% crystalline. 15. The device of claim 1, wherein the polymer comprises a PLGA copolymer. 16. The device of claim 1, wherein the coating comprises a first PLGA copolymer with a ratio of about 40:60 to about 60:40 and a second PLGA copolymer with a ratio of about 60:40 to about 90:10. 17. The device of claim 1, wherein the coating comprises a first PLGA copolymer having a molecular weight of about 10 kD and a second polymer is a PLGA copolymer having a molecular weight of about 19 kD. 18. The device of claim 1, wherein the bioabsorbable polymer is selected from the group PLGA, PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e-caprolactone) PDO, poly(dioxolane) PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid). 19. The device of claim 1, wherein the stent is formed of stainless steel material. 20. The device of claim 1, wherein the stent is formed of a material comprising a cobalt chromium alloy. 21. The device of claim 1, wherein the stent is formed from a material comprising the following percentages by weight: about 0.05 to about 0.15 C, about 1.00 to about 2.00 Mn, about 0.04 Si, about 0.03 P, about 0.3 S, about 19.0 to about 21.0 Cr, about 9.0 to about 11.0 Ni, about 14.0 to about 16.00 W, about 3.0 Fe, and Bal. Co. 22. The device of claim 1, wherein the stent is formed from a material comprising at most the following percentages by weight: about 0.025 C, about 0.15 Mn, aboout 0.15 Si, about 0.015 P, about 0.01 S, about 19.0 to about 21.0 Cr, about 33 to about 37 Ni, about 9.0 to about 10.5 Mo, about 1.0 Fe, about 1.0 Ti, and Bal. Co. 23. The device of claim 1, wherein the stent is formed from a material comprising L605 alloy. 24. The device of claim 1, wherein the stent has a thickness of from about 50% to about 90% of a total thickness of the device. 25. The device of claim 1, wherein the device has a thickness of from about 20 μm to about 500 μm. 26. The device of claim 1, wherein the stent has a thickness of from about 50 μm to about 80 μm. 27. The device of claim 1, wherein the coating has a total thickness of from about 5 μm to about 50 μm. 28. The device of claim 1, wherein the device has an active agent content of from about 5 μg to about 500 μg. 29. The device of claim 1, wherein said outer layer comprising at least one bioabsorbable polymer has a thickness of less than about 5 μm. 30. The device of claim 1, wherein the active agent is selected from rapamycin, a prodrug, a derivative, an analog, a hydrate, an ester, and a salt thereof. 31. The device of claim 1, wherein the active agent is selected from one or more of sirolimus, everolimus, zotarolimus and biolimus. 32. The device of claim 1, wherein the macrolide immunosuppressive drug comprises one or more of rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl) rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin, 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin 40-O-(6-Hydroxy)hexyl-rapamycin, 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin, 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolimus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof. 33. A device comprising a. a stent; andb. a coating on the stent comprising five layers: a first layer comprising at least one polymer; a second layer comprising at least one active agent; a third layer comprising at least one polymer; a fourth layer comprising at least one active agent; and an outer layer comprising at least one polymer; wherein each of said polymer layers comprises a separately sintered polymer layer;wherein said outer layer comprising said at least one polymer is sufficiently thin so that the active agent is present in crystalline form on at least one region of an outer surface of the coating opposite the stent and wherein between 25% and 50% of the total amount of active agent in the coating is released after 24 hours in vitro elution;wherein the active agent comprises a macrolide immunosuppressive (limus) drug. 34. The device of claim 33, wherein the polymer comprises is at least one of: a fluoropolymer, PVDF-HFP comprising vinylidene fluoride and hexafluoropropylene monomers, PC (phosphorylcholine), Polysulfone, polystyrene-b-isobutylene-b-styrene, PVP (polyvinylpyrrolidone), alkyl methacrylate, vinyl acetate, hydroxyalkyl methacrylate, and alkyl acrylate. 35. The device of claim 34, wherein the alkyl methacrylate comprises at least one of methyl methacrylate, ethyl methacrylate, propyl methacrylate, butyl methacrylate, hexyl methacrylate, octyl methacrylate, dodecyl methacrylate, and lauryl methacrylate; and wherein the alkyl acrylate comprises at least one of methyl acrylate, ethyl acrylate, propyl acrylate, butyl acrylate, hexyl acrylate, octyl acrylate, dodecyl acrylates, and lauryl acrylate. 36. The device of claim 33, wherein the polymer is not a polymer selected from: PBMA (poly n-butyl methacrylate), Parylene C, and polyethylene-co-vinyl acetate. 37. The device of claim 33, wherein the polymer comprises a durable polymer. 38. The device of claim 33, wherein the polymer comprises a bioabsorbable polymer. 39. The device of claim 38, wherein the bioabsorbable polymer is selected from the group PLGA, PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e-caprolactone) PDO, poly(dioxolane) PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid). 40. The device of claim 33, wherein in vitro elution is carried out in a 1:1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37° C.; wherein the amount of active agent released is determined by measuring UV absorption. 41. The device of claim 33, wherein the active agent is at least 50% crystalline. 42. The device of claim 33, wherein the active agent is at least 75% crystalline. 43. The device of claim 33, wherein the active agent is at least 90% crystalline. 44. The device of claim 33, wherein the stent is formed of at least one of stainless steel material and a cobalt chromium alloy. 45. The device of claim 33, wherein the stent has a thickness of from about 50% to about 90% of a total thickness of the device. 46. The device of claim 33, wherein the device has a thickness of from about 20 μm to about 500 μm. 47. The device of claim 33, wherein the stent has a thickness of from about 50 μm to about 80 μm. 48. The device of claim 33, wherein the coating has a total thickness of from about 5 μm to about 50 μm. 49. The device of claim 33, wherein the device has an active agent content of from about 5 μg to about 500 μg. 50. The device of claim 33, wherein the outer layer comprising at least one polymer has a thickness of less than about 5 μm. 51. The device of claim 33, wherein the active agent is selected from rapamycin, a prodrug, a derivative, an analog, a hydrate, an ester, and a salt thereof. 52. The device of claim 33, wherein the macrolide immunosuppressive drug comprises one or more of rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin, 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin 40-O-(6-Hydroxy)hexyl-rapamycin, 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin, 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolimus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (239)
Fenster, Aaron; Downey, Donal B., 3D ultrasound-guided intraoperative prostate brachytherapy.
Roby Mark S. (Killingworth CT) Bennett Steven L. (New Haven CT) Liu Cheng-Kung (Norwalk CT), Absorbable block copolymers and surgical articles fabricated therefrom.
Krezanoski Joseph Z. (Los Altos CA), Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery t.
Wang James C. (Norton) Roberts George R. (Arlington) Pederson ; Sr. Brian A. (So. Attleboro MA), Co-extruded medical balloons and catheter using such balloons.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L., Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent.
Liu Cheng-Kung (Norwalk CT) Jiang Ying (North Haven CT) Roby Mark S. (Killingworth CT) Bennett Steven L. (New Haven CT) Stevenson Richard P. (Colchester CT) Pietrangeli Jeffrey P. (Bridgeport CT), Composite bioabsorbable materials and surgical articles made therefrom.
Loscalzo, Joseph; Vita, Joseph A.; Loberg, Michael D.; Worcel, Manuel, Composition for treating vascular diseases characterized by nitric oxide insufficiency.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Appel, Leah E.; Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S.; Thombre, Avinash G., Controlled release by extrusion of solid amorphous dispersions of drugs.
Chandrashekar Bhagya L. ; Zhou Mingxing ; Jarr Eileen M. ; Dunn Richard L., Controlled release liquid delivery compositions with low initial drug burst.
Merida A. D'Augustine ; James H. Liu ; Donald C. Harrison, Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections.
Burke,Sandra E.; Cromack,Keith R.; Mack,Matthew; Toner,John L., Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens.
Hoy Kenneth L. (St. Albans WV) Nielsen Kenneth A. (Charleston WV), Electrostatic liquid spray application of coating with supercritical fluids as diluents and spraying from an orifice.
Palmaz, Julio C.; Boyle, Christopher T.; Banas, Christopher E.; Wiseman, Roger W.; Marton, Denes, Endoluminal implantable devices and method of making same.
Francis Moussy ; Donald Kreutzer ; Diane Burgess ; Jeffrey Koberstein ; Fotios Papadimitrakopoulos ; Samuel Huang, Implant coating for control of tissue/implant interactions.
Yoon Seok-Joon,KRX ; Yeo Guw-Dong,KRX ; Kim You-Chan,KRX ; Seo Min-Hyo,KRX ; Pai Chaul-Min,KRX ; Jung Jong-Pyoung,KRX ; Lee Seung-Jin,KRX, Implantable bioresorbable membrane and method for the preparation thereof.
McNaughton Allen D. (Mountain View CA) Albert Stephen B. (Redwood City CA) Furbershaw Gerard A. (Santa Clara CA), Implanting device and implant magazine.
Canham, Leigh T; Barrett, Christopher P; Cox, Timothy I; Wright, Peter J; Bowditch, Andrew P, Implants for administering substances and methods of producing implants.
Tice Thomas R. (Birmingham AL) Lewis Danny H. (Gardendale AL) Cowsar Donald R. (Birmingham AL) Beck Lee R. (Birmingham AL), Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Fogarty Thomas J. (770 Welch Rd. Palo Alto CA 94305) Finn ; III James C. (Stanford CA) Kinney Thomas B. (Mountain View CA), Inverted balloon catheter having sealed through lumen.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Mistrater Alan B. (Rochester NY) Pietrzykowski ; Jr. Stanley J. (Rochester NY) Klein Alfred O. (Rochester NY) Hendrix Loren E. (Webster NY) Petropoulos Mark C. (Ontario NY) Batt Gary A. (Fairport NY), Mandrel with flared, dish shaped disk and process for using mandrel.
Shaw, Wendy J.; Yonker, Clement R.; Fulton, John L.; Tarasevich, Barbara J.; McClain, James B.; Taylor, Doug, Medical implants and methods of making medical implants.
Whitbourne, Richard J.; Chamberlain, Alexandra M.; Hullihen, Daniel G.; Rosebrough, Scott F.; Calistri-Yeh, Mildred, Medicated stent having multi-layer polymer coating.
Pletcher Timothy Allen ; Datta Pabitra ; Poux Christopher Just ; McCoy Randall Eugene, Method and apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate.
Burnham, Theodore A.; Cha, Sung W.; Walat, Robert H.; Kim, Roland Y.; Anderson, Jere R.; Stevenson, James F.; Suh, Nam P.; Pallaver, Matthew, Method and apparatus for microcellular polymer extrusion.
Lars Lidgren SE; Peter Bengtsson SE; Peter Sj{overscore (o)}vall SE; Bengt Wesslen SE, Method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof.
Luzzi Louis A. ; Needham Thomas E. ; Hossein Zia ; Dondeti Polireddy, Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa.
Anderson Jere R. (Newburyport MA) Jandris Louis J. (Georgetown MA) Barbere Michael D. (Dunstable MA) Murphy Richard T. (Dracut MA 4), Method of making a distensible dilatation balloon using a block copolymer.
McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L., Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia.
DeYoung, James P.; Gross, Stephen M.; Wagner, Mark I.; McClain, James B., Methods and compositions for etch cleaning microelectronic substrates in carbon dioxide.
Roser, Bruce J.; Sanderson, Ian; Kampinga, Jaap; Colaco, Camilo, Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery.
D'Amato, Robert J.; Green, Shawn J.; Swartz, Jr., Glenn M.; Shah, Jamshed H.; Madsen, John, Methods and compositions for treating an ocular neovascular disease.
DeYoung, James P.; McClain, James B.; Gross, Stephen M.; Wagner, Mark I., Methods for transferring supercritical fluids in microelectronic and other industrial processes.
Hossainy, Syed Faiyaz Ahmed; Tang, Yiwen; Askaryar, Homayon; Lin, Qing; Glauser, Thierry, Methods of forming coatings with a crystalline or partially crystalline drug for implantable medical devices.
Cha Sung W. (Cambridge MA) Suh Nam P. (Sudbury MA) Baldwin Daniel F. (Medford MA) Park Chul B. (Cambridge MA), Microcellular thermoplastic foamed with supercritical fluid.
Kent John S. (Cupertino CA) Lewis Danny H. (Birmingham AL) Sanders Lynda M. (Palo Alto CA) Tice Thomas R. (Birmingham AL), Microencapsulation of water soluble active polypeptides.
Tepper, Gary; Pestov, Dmitry; Levit, Natalia; Wnek, Gary, Molecular imprinting of small particles, and production of small particles from solid state reactants.
Beckert, Thomas; Petereit, Hans-Ulrich; Dressman, Jennifer; Rudolph, Markus, Multi-particulate form of medicament, comprising at least two differently coated forms of pellet.
Maxfield MacRae (Plainfield NJ) Christiani Brian R. (Maplewood NJ) Murthy Sanjeeva N. (Neshanic Station NJ) Tuller Harold (Long Valley NJ), Nanocomposites of gamma phase polymers containing inorganic particulate material.
Haslam John L. (Lawrence KS) Higuchi Takeru (Lawrence KS) Mlodozeniec Arthur R. (Lawrence KS), Ophthalmic drug delivery system utilizing thermosetting gels.
Cecchi, Roberto; Croci, Tiziano; Guzzi, Umberto; Marsault, Eric, Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same.
Raeder-Devens, Jennifer E.; Shelso, Susan I.; Hemerick, James F.; Schneider, Eric M.; Getty, Heather L.; Borgmann, Doreen M.; Sisombath, Kakao; Helgerson, Jeffrey A., Prosthesis deployment device with translucent distal end.
Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Osborne, Thomas A.; Ragheb, Anthony O.; Roberts, Joseph W.; Voorhees, III, William D., Silver implantable medical device.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Lafont Antoine,FRX ; Vert Michel R.,FRX ; Cornhill Fredrick ; Li Suming,FRX ; Garreau Henri L.,FRX, Stent having a programmed pattern of in vivo degradation.
Fulton, John L.; Deverman, George S.; Matson, Dean W.; Yonker, Clement R.; Taylor, C. Douglas; McClain, James B.; Crowley, Joseph M., System and method for enhanced electrostatic deposition and surface coatings.
Setterstrom Jean A. ; Van Hamont John E. ; Reid Robert H. ; Jacob Elliot ; Jeyanthi Ramasubbu ; Boedeker Edgar C. ; McQueen Charles E. ; Jarboe Daniel L. ; Cassels Frederick ; Brown William ; Thies C, Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix.
Tsukashima Ross (San Diego CA) Jordan Matthew (Los Angeles CA) Jung Gordon (San Diego CA), Tri-fold balloon for dilatation catheter and related method.
Rodrigues Jose,FRX ; Belmain Daniel,FRX ; Barlet Thierry,FRX, Triboelectric projector, installation for projecting coating product and process for controlling such a projector.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.